ImmuCell Corporation
General ticker "ICCC" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $50.3M (TTM average)
ImmuCell Corporation follows the US Stock Market performance with the rate: 27.7%.
Estimated limits based on current volatility of 2.3%: low 6.54$, high 6.85$
Factors to consider:
- Total employees count: 79 (+6.8%) as of 2023
- US accounted for 91.3% of revenue in the fiscal year ended 2023-12-31
- Top business risk factors: Operational and conduct risks, Economic downturns and volatility, Product liability, Supply chain disruptions, Regulatory and compliance
- Price in estimated range
- Earnings for 9 months up through Q3 exceed our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2024-12-31 to 2026-12-31
- 2024-12-31 to 2025-12-31 estimated range: [4.26$, 7.86$]
- 2025-12-31 to 2026-12-31 estimated range: [4.19$, 7.81$]
Financial Metrics affecting the ICCC estimates:
- Positive: with PPE of -16.3 at the end of fiscal year the price was neutral
- Negative: negative Operating income
- Positive: -4.41 < Investing cash flow per share per price, % of -1.20
- Positive: Interest expense per share per price, % of 1.48 <= 3.31
- Negative: negative Industry operating cash flow (median)
- Negative: negative Net income
- Positive: 42.53 < Shareholder equity ratio, % of 61.02 <= 64.17
- Positive: 0.04 < Operating cash flow per share per price, % of 0.93
Short-term ICCC quotes
Long-term ICCC plot with estimates
Financial data
| YTD | 2022-12-31 | 2023-12-31 | 2024-12-31 |
|---|---|---|---|
| Operating Revenue | $18.57MM | $17.47MM | $26.49MM |
| Operating Expenses | $20.87MM | $23.22MM | $28.13MM |
| Operating Income | $-2.30MM | $-5.75MM | $-1.64MM |
| Non-Operating Income | $-0.19MM | $-0.02MM | $-0.51MM |
| Interest Expense | $0.00MM | $0.00MM | $0.57MM |
| R&D Expense | $4.49MM | $4.39MM | $3.90MM |
| Income(Loss) | $-2.49MM | $-5.77MM | $-2.15MM |
| Taxes | $0.01MM | $0.00MM | $0.01MM |
| Profit(Loss)* | $-2.49MM | $-5.77MM | $-2.16MM |
| Stockholders Equity | $30.38MM | $24.99MM | $27.52MM |
| Inventory | $6.04MM | $7.81MM | $7.11MM |
| Assets | $44.86MM | $43.81MM | $45.10MM |
| Operating Cash Flow | $-1.54MM | $-4.67MM | $0.36MM |
| Capital expenditure | $3.98MM | $1.89MM | $0.47MM |
| Investing Cash Flow | $-3.96MM | $-1.89MM | $-0.46MM |
| Financing Cash Flow | $1.11MM | $1.75MM | $2.88MM |
| Earnings Per Share** | $-0.32 | $-0.75 | $-0.26 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.